Clinical trials: Locoregional Neoplasm Recurrence
Head and Neck Neoplasms
Docetaxel in Squamous Cell Carcinoma of the Head and Neck (TAX + Cisplatin in SCCHN)
Study Objectives: To determine the MTD (maximal tolerated dose) and recommended dose of a weekly docetaxel and cisplatin combination regimen for locoregional recurrent/metastatic Squamous Cell Carcinoma of the Head and Neck…
- Trial name
- NCT00268671
- Testing
- Docetaxel
- Volunteers
- 45 people
- Sponsor
- Sanofi
Colorectal Neoplasms
Aroplatin and Capecitabine in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies
This study is a Phase I/II study. In Phase I of this study, the objective is to determine the maximum tolerated dose (MTD) of combination therapy with Aroplatin and capecitabine in subjects with unresectable, local recurrence or…
- Trial name
- NCT00081536
- Testing
- Aroplatin (Liposomal NDDP) in combination with capecitabine
- Volunteers
- 105 people
- Sponsor
- Aronex Pharmaceuticals
Recurrent Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8
NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer
This phase I trial investigates the best dose and side effects of NBTXR3 when given together with radiation therapy for the treatment of non-small cell lung cancer that cannot be treated by surgery (inoperable) and has come back…
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8
- Trial name
- NCT04505267
- Testing
- Hafnium Oxide-containing Nanoparticles NBTXR3, Radiation Therapy
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Early Breast Cancer
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who…
- Trial name
- CAMBRIA-1 (NCT05774951)
- Testing
- Camizestrant, Tamoxifen, Anastrozole
- Where
- 709 sites in United States, Argentina and 37 more
- Volunteers
- 4,300 people
- Sponsor
- AstraZeneca
Adult Solid Tumor
CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2
The purpose of this study is to test the CANscript™ sensitivity assay, which is a new and different assay developed to test the sensitivity of different cancer types to physician selected therapies (both drugs and/or drug…
- Trial name
- ANCERS-2 (NCT03253575)
- Testing
- CANscript
- Where
- 30 sites in United States
- Volunteers
- 800 people
- Sponsor
- Mitra RxDx, Inc.
Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma
Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma
This randomized phase III trial compares two different high-dose chemotherapy regimens followed by a stem cell transplant in treating younger patients with high-risk neuroblastoma.
- Conditions
- Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma
- Trial name
- NCT00567567
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin
- Where
- 190 sites in United States, Australia and 4 more
- Volunteers
- 665 people
- Sponsor
- Children's Oncology Group
Colorectal Carcinoma, Renal Cancer
Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study)
The goal of this single-center observational cohort study, based on a registry combining retrospectively and prospectively collected data, is to investigate the short- and long-term effects of irreversible electroporation (IRE)…
- Conditions
- Colorectal Carcinoma, Renal Cancer, Bladder Cancer, Cervical Cancer
- Trial name
- PELFIRE (NCT07782164)
- Testing
- Irreversible electroporation
- Where
- Netherlands
- Volunteers
- 27 people
- Sponsor
- Amsterdam UMC, location VUmc
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Anal Cancer, Carcinoma of the Appendix
Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Anal Cancer, Carcinoma of the Appendix, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT00654160
- Testing
- fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Mayo Clinic
Colorectal Cancer
Neoadjuvant Cetuximab, Fluorouracil, and Pelvic Irradiation in Treating Patients With Locally Advanced or Locally Recurrent Rectal Cancer
RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00084773
- Testing
- cetuximab, fluorouracil, neoadjuvant therapy
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cutaneous or Sub-cutaneous Malignancies
Dose Escalating Study for Amphinex-based PCI of Bleomycin.
The primary goal of this extension study is to further investigate the tolerability and efficacy in a phase I setting in order to see whether lower doses than the initial study dose of 0.25 mg/kg bw Amphinex in Amphinex-based PCI…
- Trial name
- NCT01872923
- Testing
- Amphinex, Bleomycin, Laser
- Where
- United Kingdom
- Volunteers
- 3 people
- Sponsor
- PCI Biotech AS
Esophageal Cancer
To Observe the Benefit of Adding Brachytherapy After CCRT on Resectable Esophageal Cancer Patients Without Surgery
Clinical experience of adding intraluminal brachytherapy with traditional applicator after definitive concurrent chemoradiotherapy (CCRT) for local-regional thoracic esophageal cancer is limited due to high complication risk and…
- Trial name
- NCT05145647
- Testing
- Add-on Brachytherapy, "BRAXX" Esophageal Brachytherapy Applicator
- Where
- Taiwan
- Volunteers
- 18 people
- Sponsor
- Chang Gung Memorial Hospital
Prostate Cancer
Feasibility Study on the Use of PET-MRI / 68Ga-PSMA Imaging for HIFU-focal Treatment in the Event of Recurrent Prostate Cancer After Radiotherapy - PSMA Study
A significant proportion of patients with localized prostate cancer, and treated for curative intent by radiotherapy, have a local recurrence.
- Trial name
- PSMA (NCT03927521)
- Testing
- Focal HIFU using PET-MRI/68Ga-PSMA imaging guidance
- Where
- France
- Volunteers
- 11 people
- Sponsor
- Hospices Civils de Lyon
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have…
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00006026
- Testing
- rubitecan
- Where
- 11 sites in Belgium, France and 5 more
- Volunteers
- 21 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Recurrent Glioblastoma
Tris-CAR-T Cell Therapy for Recurrent Glioblastoma
This is a Phase 1 study of recurrent glioblastoma locoregional adoptive therapy with autologous peripheral blood T cells lentivirally transduced to express a dual-target, truncated IL7Ra modified chimeric antigen receptor (CAR)…
- Trial name
- NCT05577091
- Testing
- Inverse correlated dual-target, truncated IL7Ra modified CAR -expressing autologous T-lymphocytes.
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Beijing Tiantan Hospital
Recurrent Head and Neck Cancer, Local Cryotherapy Treatment
Evaluation of the Efficacy and Safety of Local Cryotherapy Treatment of Recurrent Head and Neck Cancer in Irradiated Areas: a Pilot Study
In France, squamous cell carcinomas of the head and neck (SCCHN) are the 5th most common cancer. 60% of patients present with locally advanced tumors (stage III/IV), characterized by a poor prognosis (5-year survival not…
- Trial name
- CRYORL (NCT05738187)
- Testing
- local cryotherapy treatment
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Strasbourg, France
Non-Small-Cell Lung Carcinoma
Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence
The goal of this clinical research study is to learn if, compared with regular x-ray radiation, proton radiation reduces the risk of developing, treatment-related pneumonitis (TRP) or tumor recurrence (the tumor coming back in…
- Trial name
- NCT00915005
- Testing
- Photon Therapy, Proton Therapy, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 275 people
- Sponsor
- M.D. Anderson Cancer Center
Survival, Postoperative Morbidity
Abdominal or Transanal TME for Rectal Cancer Therapy
This study assessed whether transanal TME in patients with rectal cancer is superior to open, laparoscopic, and robotic TME (abdominal TME (abTME)) regarding oncological outcome, postoperative morbidity and 90-day mortality.
- Conditions
- Survival, Postoperative Morbidity, Mortality, Recurrence
- Trial name
- NCT04969107
- Testing
- taTME, abdTME
- Where
- Switzerland
- Volunteers
- 300 people
- Sponsor
- Cantonal Hospital of St. Gallen
Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
This partially randomized phase III trial studies isotretinoin with dinutuximab, aldesleukin, and sargramostim to see how well it works compared to isotretinoin alone following stem cell transplant in treating patients with…
- Conditions
- Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma
- Trial name
- NCT00026312
- Testing
- Aldesleukin, Dinutuximab, Isotretinoin
- Where
- 197 sites in United States, Australia and 3 more
- Volunteers
- 1,449 people
- Sponsor
- National Cancer Institute (NCI)
Locoregional Recurrence
Locoregional Recurrence of Breast Cancer
our study will be retrospective on breast cancer patients to detect relation between the locoregional recurrence of breast cancer after radiotherapy and the molecular subtypes
- Trial name
- NCT05988112
- Volunteers
- 265 people
- Sponsor
- Assiut University